Registration — BROWNSTEIN HYATT FARBER SCHRECK, LLP for NEUROMOLECULAR PHARMACEUTICALS (2007)

Firm

BROWNSTEIN HYATT FARBER SCHRECK, LLP

Client

NEUROMOLECULAR PHARMACEUTICALS

Income

—

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

Marketing of antiviral therapy for the H5N1 Avian Flu virus

Lobbyist	Covered position, as disclosed
JUDY BLACK New	N/A
DAVID PHILLIP COHEN New	N/A
TERESA DYER New	N/A
C SUZANNE MENCER New	N/A
PAMELA SILLARS New	N/A

Pharmacy PHA

Marketing of antiviral therapy for the H5N1 Avian Flu virus

Lobbyist	Covered position, as disclosed
JUDY BLACK New	N/A
DAVID PHILLIP COHEN New	N/A
TERESA DYER New	N/A
C SUZANNE MENCER New	N/A
PAMELA SILLARS New	N/A

Medical/Disease Research/Clinical Labs MED

Marketing of antiviral therapy for the H5N1 Avian Flu virus

Lobbyist	Covered position, as disclosed
JUDY BLACK New	N/A
DAVID PHILLIP COHEN New	N/A
TERESA DYER New	N/A
C SUZANNE MENCER New	N/A
PAMELA SILLARS New	N/A

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.